Layered Precision Therapy for Advanced IgAN Beyond Trial Eligibility: Thirteen-Month Real-World Experience with Targeted-Release Formulation (TRF)-Budesonide and Atrasentan (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0520; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Individualized dosing of TRF-budesonide and ongoing low-dose corticosteroid tapering reflect real-world complexity absent from trial protocols. These findings support cautious extension of layered precision therapy to advanced IgAN and underscore the need for prospective studies in this high-risk, underserved population."
Clinical • Metastases • Real-world • Real-world evidence • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Renal Disease
|
|
Tyng-shiuan Gau; Fan-Chi Chang
|